Different Strategies for the Treatment of Age-Related Macular Degeneration in China: An Economic Evaluation
Purpose. To assess the cost-effectiveness of bevacizumab compared to ranibizumab, verteporfin photodynamic therapy (PDT), and usual care for the treatment of age-related macular degeneration (AMD) in China. Methods. A Markov model was developed according to patient visual acuity (VA) in the better-s...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2016-01-01
|
| Series: | Journal of Ophthalmology |
| Online Access: | http://dx.doi.org/10.1155/2016/7689862 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832551847442776064 |
|---|---|
| author | Bin Wu Jin Li Houwen Lin Haixiang Wu |
| author_facet | Bin Wu Jin Li Houwen Lin Haixiang Wu |
| author_sort | Bin Wu |
| collection | DOAJ |
| description | Purpose. To assess the cost-effectiveness of bevacizumab compared to ranibizumab, verteporfin photodynamic therapy (PDT), and usual care for the treatment of age-related macular degeneration (AMD) in China. Methods. A Markov model was developed according to patient visual acuity (VA) in the better-seeing eye (Snellen scale). Four cohorts of patients were treated with one of the following therapies: bevacizumab, ranibizumab, PDT, or usual care. Clinical data related to treatments were obtained from published randomized clinical trials. Direct medical costs and resource utilization in the Chinese health care setting were taken into account. Health and economic outcomes were evaluated over a lifetime horizon. Sensitivity analyses were performed. Results. Treatment with ranibizumab provided the greatest gains in quality-adjusted life-years (QALYs). The cost per marginal QALY gained with bevacizumab over usual care was $1,258, $3,803, and $2,066 for the predominantly classic, minimally classic, and occult lesions, respectively. One-way sensitivity analysis showed considerably influential factors, such as utility values and effectiveness data. Probabilistic sensitivity analysis indicated that, compared to usual care, PDT and ranibizumab most cases would be cost-effective in the bevacizumab arm at a threshold of $7,480/QALY. Conclusion. Bevacizumab can be a cost-effective option for the treatment of AMD in the Chinese setting. |
| format | Article |
| id | doaj-art-f06dec7299cb498a989923d8c31b534a |
| institution | Kabale University |
| issn | 2090-004X 2090-0058 |
| language | English |
| publishDate | 2016-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Journal of Ophthalmology |
| spelling | doaj-art-f06dec7299cb498a989923d8c31b534a2025-02-03T06:00:23ZengWileyJournal of Ophthalmology2090-004X2090-00582016-01-01201610.1155/2016/76898627689862Different Strategies for the Treatment of Age-Related Macular Degeneration in China: An Economic EvaluationBin Wu0Jin Li1Houwen Lin2Haixiang Wu3Medical Decision and Economic Group, Department of Pharmacy, Ren Ji Hospital, South Campus, School of Medicine, Shanghai Jiaotong University, Shanghai 201114, ChinaDepartment of Ophthalmology, Ren Ji Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai 200127, ChinaMedical Decision and Economic Group, Department of Pharmacy, Ren Ji Hospital, South Campus, School of Medicine, Shanghai Jiaotong University, Shanghai 201114, ChinaDepartment of Ophthalmology, Eye & ENT Hospital, Fudan University, Shanghai 200031, ChinaPurpose. To assess the cost-effectiveness of bevacizumab compared to ranibizumab, verteporfin photodynamic therapy (PDT), and usual care for the treatment of age-related macular degeneration (AMD) in China. Methods. A Markov model was developed according to patient visual acuity (VA) in the better-seeing eye (Snellen scale). Four cohorts of patients were treated with one of the following therapies: bevacizumab, ranibizumab, PDT, or usual care. Clinical data related to treatments were obtained from published randomized clinical trials. Direct medical costs and resource utilization in the Chinese health care setting were taken into account. Health and economic outcomes were evaluated over a lifetime horizon. Sensitivity analyses were performed. Results. Treatment with ranibizumab provided the greatest gains in quality-adjusted life-years (QALYs). The cost per marginal QALY gained with bevacizumab over usual care was $1,258, $3,803, and $2,066 for the predominantly classic, minimally classic, and occult lesions, respectively. One-way sensitivity analysis showed considerably influential factors, such as utility values and effectiveness data. Probabilistic sensitivity analysis indicated that, compared to usual care, PDT and ranibizumab most cases would be cost-effective in the bevacizumab arm at a threshold of $7,480/QALY. Conclusion. Bevacizumab can be a cost-effective option for the treatment of AMD in the Chinese setting.http://dx.doi.org/10.1155/2016/7689862 |
| spellingShingle | Bin Wu Jin Li Houwen Lin Haixiang Wu Different Strategies for the Treatment of Age-Related Macular Degeneration in China: An Economic Evaluation Journal of Ophthalmology |
| title | Different Strategies for the Treatment of Age-Related Macular Degeneration in China: An Economic Evaluation |
| title_full | Different Strategies for the Treatment of Age-Related Macular Degeneration in China: An Economic Evaluation |
| title_fullStr | Different Strategies for the Treatment of Age-Related Macular Degeneration in China: An Economic Evaluation |
| title_full_unstemmed | Different Strategies for the Treatment of Age-Related Macular Degeneration in China: An Economic Evaluation |
| title_short | Different Strategies for the Treatment of Age-Related Macular Degeneration in China: An Economic Evaluation |
| title_sort | different strategies for the treatment of age related macular degeneration in china an economic evaluation |
| url | http://dx.doi.org/10.1155/2016/7689862 |
| work_keys_str_mv | AT binwu differentstrategiesforthetreatmentofagerelatedmaculardegenerationinchinaaneconomicevaluation AT jinli differentstrategiesforthetreatmentofagerelatedmaculardegenerationinchinaaneconomicevaluation AT houwenlin differentstrategiesforthetreatmentofagerelatedmaculardegenerationinchinaaneconomicevaluation AT haixiangwu differentstrategiesforthetreatmentofagerelatedmaculardegenerationinchinaaneconomicevaluation |